The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

American pharmaceutical company Moderna (MRNA) is reportedly under scrutiny by U.S. President Donald Trump’s team, which is ...

The U.S. government awarded Moderna $590 million in January to advance the development of its bird flu vaccine ...

(Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna (NASDAQ: MRNA) for the ...

The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered Moderna's Covid vaccine, the report added. The U.S. government awarded ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for ...

Moderna is one of the pharmaceutical companies best known for developing the messenger RNA vaccine against Covid-19.

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.